Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US
Executive Summary
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.
You may also be interested in...
Celltrion Eyes Price Advantage For ‘Latecomer’ Bevacizumab
Celltrion has indicated that it intends to leverage its ability to compete on cost to gain a foothold in the bevacizumab market, despite being a “latecomer” in the wake of firms that have previously launched and filed biosimilar rivals to Avastin.
Amneal Takes A Step Forward On Biosimilars
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.
Centus Settles US Litigation Over Avastin
Centus Biotherapeutics and Roche’s Genentech have agreed to settle US patent litigation over the biosimilars firm’s FKB238 proposed bevacizumab rival to Avastin.